[Vitamin K for newborn infants: why and how?]. / Vitamin K für Neugeborene: Warum und wie?
Kinderarztl Prax
; 61(7-8): 258-63, 1993 Oct.
Article
en De
| MEDLINE
| ID: mdl-8271675
Several publications during the past 10-15 years report on the identification of acarboxyprothrombin (PIVKA II) in a varying proportion of examined newborn and babies (1.9 to 81.5%). These findings prove that the relevant infants were suffering from vitamin K deficiency. Hence, the researchers recommend to continue the prophylactic administration of Vitamin K to newborn. Another argument in favour of vitamin K prophylaxis is supplied by the results of epidemiological studies on the frequency of haemorrhages in newborn and babies caused by vitamin K deficiency. In respect of avoidance of haemorrhages, a single intramuscular injection of vitamin K appears to be the safest mode of application, but repeated peroral administration seems to be practically equally effective. The very frequently performed intramuscular injection of vitamin K is criticised not only because of possible local complications but also because of the greatly enhanced vitamin K concentrations in the blood after the injection. This enhanced concentration is accused of being responsible for the increased risk of malignant tumour growth in those babies who received vitamin K via the i.m. route, compared with the children who had not been given any injection or to whom vitamin K had been administered orally. For this reason vitamin K prophylaxis should be effected in newborn via the oral route (repeated administration), whereas the i.m. route should be an exception. Recommendations to this effect are already on record.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Vitamina K
/
Deficiencia de Vitamina K
Tipo de estudio:
Guideline
/
Prognostic_studies
Límite:
Humans
/
Newborn
Idioma:
De
Revista:
Kinderarztl Prax
Año:
1993
Tipo del documento:
Article
Pais de publicación:
Alemania